🎉 M&A multiples are live!
Check it out!

Champions Oncology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Champions Oncology and similar public comparables like Dishman Carbogen Amics, Syngene International, and Suven Pharma.

Champions Oncology Overview

About Champions Oncology

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.


Founded

1985

HQ

United States of America
Employees

210

Financials

LTM Revenue $56.3M

LTM EBITDA $5.5M

EV

$112M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Champions Oncology Financials

Champions Oncology has a last 12-month revenue of $56.3M and a last 12-month EBITDA of $5.5M.

In the most recent fiscal year, Champions Oncology achieved revenue of $50.2M and an EBITDA of -$5.1M.

Champions Oncology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Champions Oncology valuation multiples based on analyst estimates

Champions Oncology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $53.9M $50.2M XXX XXX XXX
Gross Profit $25.5M $24.3M XXX XXX XXX
Gross Margin 47% 49% XXX XXX XXX
EBITDA -$2.2M -$5.1M XXX XXX XXX
EBITDA Margin -4% -10% XXX XXX XXX
Net Profit $0.5M -$5.3M XXX XXX XXX
Net Margin 1% -11% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Champions Oncology Stock Performance

As of April 15, 2025, Champions Oncology's stock price is $8.

Champions Oncology has current market cap of $109M, and EV of $112M.

See Champions Oncology trading valuation data

Champions Oncology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$112M $109M XXX XXX XXX XXX $0.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Champions Oncology Valuation Multiples

As of April 15, 2025, Champions Oncology has market cap of $109M and EV of $112M.

Champions Oncology's trades at 2.0x LTM EV/Revenue multiple, and 20.3x LTM EBITDA.

Analysts estimate Champions Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Champions Oncology and 10K+ public comps

Champions Oncology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $112M XXX XXX XXX
EV/Revenue 2.1x XXX XXX XXX
EV/EBITDA 49.3x XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Champions Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Champions Oncology Valuation Multiples

Champions Oncology's NTM/LTM revenue growth is 8%

Champions Oncology's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Champions Oncology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Champions Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Champions Oncology and other 10K+ public comps

Champions Oncology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -7% XXX XXX XXX XXX
EBITDA Margin 4% XXX XXX XXX XXX
EBITDA Growth 129% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 12% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 14% XXX XXX XXX XXX
G&A Expenses to Revenue 22% XXX XXX XXX XXX
R&D Expenses to Revenue 19% XXX XXX XXX XXX
Opex to Revenue 55% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Champions Oncology Public Comps

See public comps and valuation multiples for Contract Research & Manufacturing and Health Data & Analytics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Jubilant Pharmova XXX XXX XXX XXX XXX XXX
Biocon XXX XXX XXX XXX XXX XXX
Syngene International XXX XXX XXX XXX XXX XXX
Dishman Carbogen Amics XXX XXX XXX XXX XXX XXX
Suven Pharma XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Champions Oncology M&A and Investment Activity

Champions Oncology acquired  XXX companies to date.

Last acquisition by Champions Oncology was  XXXXXXXX, XXXXX XXXXX XXXXXX . Champions Oncology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Champions Oncology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Champions Oncology

When was Champions Oncology founded? Champions Oncology was founded in 1985.
Where is Champions Oncology headquartered? Champions Oncology is headquartered in United States of America.
How many employees does Champions Oncology have? As of today, Champions Oncology has 210 employees.
Who is the CEO of Champions Oncology? Champions Oncology's CEO is Dr. Ronnie Morris, M.D..
Is Champions Oncology publicy listed? Yes, Champions Oncology is a public company listed on NAS.
What is the stock symbol of Champions Oncology? Champions Oncology trades under CSBR ticker.
When did Champions Oncology go public? Champions Oncology went public in 2007.
Who are competitors of Champions Oncology? Similar companies to Champions Oncology include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics.
What is the current market cap of Champions Oncology? Champions Oncology's current market cap is $109M
What is the current revenue of Champions Oncology? Champions Oncology's last 12-month revenue is $56.3M.
What is the current EBITDA of Champions Oncology? Champions Oncology's last 12-month EBITDA is $5.5M.
What is the current EV/Revenue multiple of Champions Oncology? Current revenue multiple of Champions Oncology is 2.0x.
What is the current EV/EBITDA multiple of Champions Oncology? Current EBITDA multiple of Champions Oncology is 20.3x.
What is the current revenue growth of Champions Oncology? Champions Oncology revenue growth between 2023 and 2024 was -7%.
Is Champions Oncology profitable? Yes, Champions Oncology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.